Kirsten rat sarcoma (KRAS) mutation has been found to be an initiating genetic event for the majority of pancreatic ductal adenocarcinomas, with 95% of pancreatic intraepithelial neoplasms harboring KRAS mutations on chromosome 12 [7]. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.